NFKB1

Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), also known as NFKB1, is a human gene.

Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
File:PBB Protein NFKB1 image.jpg PDB rendering based on 1bfs.
Available structures PDB Ortholog search: Template:Homologene2PDBe PDBe, Template:Homologene2uniprot RCSB List of PDB id codes 1bfs​, 1ikn​, 1le5​, 1le9​, 1lei​, 1nfi​, 1nfk​, 1ooa​, 1svc​, 1u36​, 1u3j​, 1u3y​, 1u3z​, 1u41​, 1u42​, 1vkx​, 2dbf​, 2i9t​
Identifiers
Symbols	NFKB1 ; DKFZp686C01211; EBP-1; KBF1; MGC54151; NF-kappa-B; NFKB-p105; NFKB-p50
External IDs	Template:OMIM5 Template:MGI HomoloGene: 2971
Gene ontology Molecular function Template:GNF GO Template:GNF GO Template:GNF GO Cellular component Template:GNF GO Template:GNF GO Biological process Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO
RNA expression pattern
File:PBB GE NFKB1 209239 at.png
More reference expression data
Orthologs
Template:GNF Ortholog box
Species	Human	Mouse
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Location (UCSC)	n/a	n/a
PubMed search	n/a	n/a

This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth.

Further reading

• Baldwin AS (1996). "The NF-kappa B and I kappa B proteins: new discoveries and insights". Annu. Rev. Immunol. 14: 649–83. doi:10.1146/annurev.immunol.14.1.649. PMID 8717528.
• Snásel J, Pichová I (1997). "The cleavage of host cell proteins by HIV-1 protease". Folia Biol. (Praha). 42 (5): 227–30. PMID 8997639.
• Chen F, Castranova V, Shi X, Demers LM (1999). "New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases". Clin. Chem. 45 (1): 7–17. PMID 9895331.CS1 maint: Multiple names: authors list (link)
• Bottex-Gauthier C, Pollet S, Favier A, Vidal DR (2002). "[The Rel/NF-kappa-B transcription factors: complex role in cell regulation]". Pathol. Biol. 50 (3): 204–11. PMID 11980335.CS1 maint: Multiple names: authors list (link)
• Garg A, Aggarwal BB (2002). "Nuclear transcription factor-kappaB as a target for cancer drug development". Leukemia. 16 (6): 1053–68. doi:10.1038/sj.leu.2402482. PMID 12040437.
• Sun Z, Andersson R (2003). "NF-kappaB activation and inhibition: a review". Shock. 18 (2): 99–106. PMID 12166787.
• Mercurio AM (2003). "Invasive skin carcinoma--Ras and alpha6beta4 integrin lead the way". Cancer Cell. 3 (3): 201–2. PMID 12676577.
• Sun SC, Xiao G (2004). "Deregulation of NF-kappaB and its upstream kinases in cancer". Cancer Metastasis Rev. 22 (4): 405–22. PMID 12884915.
• Kucharczak J, Simmons MJ, Fan Y, Gélinas C (2004). "To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis". Oncogene. 22 (56): 8961–82. doi:10.1038/sj.onc.1207230. PMID 14663476.CS1 maint: Multiple names: authors list (link)
• Suh J, Rabson AB (2004). "NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?". J. Cell. Biochem. 91 (1): 100–17. doi:10.1002/jcb.10729. PMID 14689584.
• Muthumani K, Desai BM, Hwang DS; et al. (2004). "HIV-1 Vpr and anti-inflammatory activity". DNA Cell Biol. 23 (4): 239–47. doi:10.1089/104454904773819824. PMID 15142381.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Schmitz ML, Mattioli I, Buss H, Kracht M (2005). "NF-kappaB: a multifaceted transcription factor regulated at several levels". Chembiochem. 5 (10): 1348–58. doi:10.1002/cbic.200400144. PMID 15457532.CS1 maint: Multiple names: authors list (link)
• Pise-Masison CA, Brady JN (2006). "Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function". Front. Biosci. 10: 919–30. PMID 15569630.
• Joseph AM, Kumar M, Mitra D (2005). "Nef: "necessary and enforcing factor" in HIV infection". Curr. HIV Res. 3 (1): 87–94. PMID 15638726.CS1 maint: Multiple names: authors list (link)
• Le Rouzic E, Benichou S (2006). "The Vpr protein from HIV-1: distinct roles along the viral life cycle". Retrovirology. 2: 11. doi:10.1186/1742-4690-2-11. PMID 15725353.
• Zhao RY, Elder RT (2005). "Viral infections and cell cycle G2/M regulation". Cell Res. 15 (3): 143–9. doi:10.1038/sj.cr.7290279. PMID 15780175.
• Zhao RY, Bukrinsky M, Elder RT (2005). "HIV-1 viral protein R (Vpr) & host cellular responses". Indian J. Med. Res. 121 (4): 270–86. PMID 15817944.CS1 maint: Multiple names: authors list (link)
• Muthumani K, Choo AY, Hwang DS; et al. (2006). "HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis". Current drug delivery. 1 (4): 335–44. PMID 16305395.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Courtois G, Smahi A (2006). "NF-kappaB-related genetic diseases". Cell Death Differ. 13 (5): 843–51. doi:10.1038/sj.cdd.4401841. PMID 16397577.
• Mattson MP, Meffert MK (2006). "Roles for NF-kappaB in nerve cell survival, plasticity, and disease". Cell Death Differ. 13 (5): 852–60. doi:10.1038/sj.cdd.4401837. PMID 16397579.
• Schmitz ML, Krappmann D (2006). "Controlling NF-kappaB activation in T cells by costimulatory receptors". Cell Death Differ. 13 (5): 834–42. doi:10.1038/sj.cdd.4401845. PMID 16410801.
• Janssens S, Tschopp J (2006). "Signals from within: the DNA-damage-induced NF-kappaB response". Cell Death Differ. 13 (5): 773–84. doi:10.1038/sj.cdd.4401843. PMID 16410802.
• Perkins ND, Gilmore TD (2006). "Good cop, bad cop: the different faces of NF-kappaB". Cell Death Differ. 13 (5): 759–72. doi:10.1038/sj.cdd.4401838. PMID 16410803.
• Weil R, Israël A (2006). "Deciphering the pathway from the TCR to NF-kappaB". Cell Death Differ. 13 (5): 826–33. doi:10.1038/sj.cdd.4401856. PMID 16439988.
• Kim HJ, Hawke N, Baldwin AS (2006). "NF-kappaB and IKK as therapeutic targets in cancer". Cell Death Differ. 13 (5): 738–47. doi:10.1038/sj.cdd.4401877. PMID 16485028.CS1 maint: Multiple names: authors list (link)
• Braun T, Carvalho G, Fabre C; et al. (2006). "Targeting NF-kappaB in hematologic malignancies". Cell Death Differ. 13 (5): 748–58. doi:10.1038/sj.cdd.4401874. PMID 16498458.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Bottero V, Withoff S, Verma IM (2006). "NF-kappaB and the regulation of hematopoiesis". Cell Death Differ. 13 (5): 785–97. doi:10.1038/sj.cdd.4401888. PMID 16528384.CS1 maint: Multiple names: authors list (link)
• Xiao G (2007). "Autophagy and NF-kappaB: fight for fate". Cytokine Growth Factor Rev. 18 (3–4): 233–43. doi:10.1016/j.cytogfr.2007.04.006. PMID 17485237.